Inventiva S.A. entered into an amendment to its Subscription Agreement with BlackRock and Claret Capital Partners on June 12, 2026, to modify the testing mechanism for its €30.0 million minimum cash covenant. The amendment also establishes the holders of Tranche B and Tranche C Amortized Bonds as a group (masse) with legal personality and provides security for monthly repayment amounts. Inventiva S.A. is a biotechnology company focused on developing and commercializing medical treatments.
